SBIR Phase I: Micro/Nanofluidic Protein Profiler for Pathogen Detection

SBIR 第一阶段：用于病原体检测的微/纳流体蛋白质分析仪

• 批准号: 0441585
• 负责人: Yan Li
• 金额: --
• 依托单位: CALIBRANT BIOSYSTEMS INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-01-01 至 2005-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0441585&HistoricalAwards=false
• 关键词: SBIR; Phase; Micro; Nanofluidic; Protein

This Small Business Innovation Research (SBIR) Phase I project will develop a micro/nano fluidic proteomic platform for pathogen detection and identification. The system is based on the use of high-resolution, two-dimensional (2-D) protein separations in disposable microfluidic chips to generate protein expression maps which may be used to identify biomarker patterns unique to specific pathogens. Effective technologies for the early detection and identification of biological warfare agents are of critical and growing importance. The novel miniaturized detection platform will be capable of meeting key requirements for universal pathogen detection with the ability to identify bacterial, viral, and protein toxin agents in a single detection platform. The system will provide identification within a short 15 minute cycle time, significantly faster than comparable microarray technologies. Furthermore, it will not employ biologically active reagents for its operation and will not require a priori knowledge of which pathogens may be present in a sample. If successful, the proposed technology will provide a unique solution for rapidly identifying environmental pathogens, with benefits for a wide range of field-deployable applications. Further miniaturization employing nanoscale detection channels with confocal scanning microscopy will enable protein profiling at the single molecule level for ultra-sensitive early pathogen detection. In addition to the need for improved pathogen detection for antiterrorism applications, there are over two million emergency response personnel located at over 90,000 public health and safety facilities who are effectively on the front lines of homeland defense, and who will directly benefit from cost-effective technologies to quickly detect or dismiss potential biowarfare threats. It is particularly vital for these personnel to have access to detection tools capable of broad spectrum pathogen detection without the need for priori knowledge of which pathogens may be present. In addition, rapid, accurate bacterial identification is critically important in applications outside of biowarfare defense. Industries which will benefit from these developments include disease diagnosis, prediction of emerging health hazards, monitoring potential food contamination, and bioprocess regulation. Furthermore, the technology in this effort will offer benefits to the biopharmaceutical industry as a proteomics tool for biomarker identification and drug discovery.

该小型企业创新研究（SBIR）第一阶段项目将开发用于病原体检测和识别的微/纳米流体蛋白质组平台。该系统基于在一次性微流控芯片中使用高分辨率、二维 (2-D) 蛋白质分离来生成蛋白质表达图，该图可用于识别特定病原体特有的生物标志物模式。早期检测和识别生物战剂的有效技术至关重要且日益重要。新型小型化检测平台将能够满足通用病原体检测的关键要求，能够在单一检测平台中识别细菌、病毒和蛋白质毒素。该系统将在短短 15 分钟的循环时间内提供识别，比同类微阵列技术快得多。 此外，它的操作不会使用生物活性试剂，并且不需要先验知识样本中可能存在哪些病原体。 如果成功，所提出的技术将为快速识别环境病原体提供独特的解决方案，并为广泛的现场部署应用带来好处。 采用纳米级检测通道和共焦扫描显微镜的进一步小型化将使单分子水平的蛋白质分析成为可能，从而实现超灵敏的早期病原体检测。 除了反恐应用需要改进病原体检测外，还有超过 200 万应急响应人员分布在 90,000 多个公共卫生和安全设施中，他们实际上处于国土防御的前线，并且将直接受益于具有成本效益的技术快速检测或消除潜在生物战威胁的技术。 对于这些人员来说，获得能够进行广谱病原体检测的检测工具尤其重要，而无需事先了解可能存在哪些病原体。 此外，快速、准确的细菌识别在生物战防御以外的应用中至关重要。将从这些发展中受益的行业包括疾病诊断、新出现的健康危害预测、潜在食品污染监测和生物过程监管。 此外，这项技术将作为生物标志物识别和药物发现的蛋白质组学工具为生物制药行业带来好处。